Trials / Conditions / Post-essential Thrombocythemia Myelofibrosis (Post-ET MF)

Post-essential Thrombocythemia Myelofibrosis (Post-ET MF)

8 registered clinical trials studyying Post-essential Thrombocythemia Myelofibrosis (Post-ET MF) — 2 currently recruiting.

Status	Trial	Sponsor	Phase
Not Yet Recruiting	Study of Pelabresib add-on to Ruxolitinib in Japanese Adult Patients With Myelofibrosis NCT07340138	Novartis Pharmaceuticals	Phase 1
Recruiting	MPN PROGRESSion Registry: Observational Study Tracking Symptoms, Treatments, and Disease Progression in People NCT07362225	MPN Research Foundation	—
Unknown	Study of KRT-232 or TL-895 in Janus Associated Kinase Inhibitor Treatment-Naïve Myelofibrosis NCT04878003	Kartos Therapeutics, Inc.	Phase 2
Completed	Jaktinib for the Treatment of Ruxolitinib Intolerance of Myelofibrosis NCT04217993	Suzhou Zelgen Biopharmaceuticals Co.,Ltd	Phase 2
Terminated	Assess the Safety, Tolerability Oral PU-H71 in Subjects Taking Ruxolitinib NCT03935555	Samus Therapeutics, Inc.	Phase 1
Active Not Recruiting	Extended Access of Momelotinib in Adults With Myelofibrosis NCT03441113	GlaxoSmithKline	Phase 2
Completed	Efficacy of Momelotinib Versus Best Available Therapy in Anemic or Thrombocytopenic Subjects With Primary Myel NCT02101268	Sierra Oncology LLC - a GSK company	Phase 3